Voyager Therapeutics, Inc, a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD101 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; Tau program for the treatment of tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia; and VY-NAV01 for severe chronic pain.
Read More…
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Phone857-259-5340
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$7.62 million
Profitability
Miscellaneous
Employees123
Next Earnings Date11/6/2019 (Estimated)
OptionableOptionable
Voyager Therapeutics (NASDAQ:VYGR) Frequently Asked Questions
What is Voyager Therapeutics' stock symbol?
Voyager Therapeutics trades on the NASDAQ under the ticker symbol "VYGR."
How were Voyager Therapeutics' earnings last quarter?
Voyager Therapeutics Inc (NASDAQ:VYGR) posted its quarterly earnings data on Friday, August, 9th. The company reported $0.29 EPS for the quarter, beating the consensus estimate of ($0.88) by $1.17. The business had revenue of $46.09 million for the quarter, compared to analysts' expectations of $5.25 million. Voyager Therapeutics had a negative net margin of 106.23% and a negative return on equity of 71.08%. View Voyager Therapeutics' Earnings History.
When is Voyager Therapeutics' next earnings date?
What price target have analysts set for VYGR?
9 Wall Street analysts have issued 1 year target prices for Voyager Therapeutics' stock. Their predictions range from $23.00 to $37.00. On average, they anticipate Voyager Therapeutics' share price to reach $28.86 in the next twelve months. This suggests a possible upside of 86.8% from the stock's current price. View Analyst Price Targets for Voyager Therapeutics.
What is the consensus analysts' recommendation for Voyager Therapeutics?
9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Voyager Therapeutics in the last year. There are currently 2 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Voyager Therapeutics.
What are Wall Street analysts saying about Voyager Therapeutics stock?
Here are some recent quotes from research analysts about Voyager Therapeutics stock:
- 1. According to Zacks Investment Research, "Voyager Therapeutics, Inc. is a gene therapy company. It focuses on the development of treatments for patients suffering from severe diseases of the central nervous system. Its pipeline includes VY-AADC01, which is in Phase 1b clinical trials for treatment of Parkinson's disease and preclinical programs comprise VY-SOD101 for a monogenic form of amyotrophic lateral sclerosis, VY-FXN01 for Friedreich ataxia and VY-HTT01 for Huntington's disease as well as VY-SMN101 for neuromuscular disease. Voyager Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. " (10/12/2019)
- 2. Nomura analysts commented, "Minor Tweaks Post-NBIX Collab., Revising Patient Numbers and Statistical Plan; No Data Guidance Yet. The first pivotal Parkinson’s disease trial, RESTORE-1, is undergoing minor modifications now that VYGR is partnered with NBIX. VYGR had previously guided to a 75-100 patient trial, but this is likely going to be clarified as the statistical analysis plan is finalized. No data guidance yet—but we expect an update when the target enrollment is finalized and when VYGR gets a sense of the pace of enrollment. Huntington’s Program IND by YE19 – Finalizing Clinical Team and Planning to Use Commercial-Grade Gene Therapy Material. Voyager recently attained full rights after the SNY collaboration restructuring (see our note here). VYGR plans to have an IND by YE19 and will use material that is “very, very similar” to commercial material to avoid any step back in the future." (8/13/2019)
- 3. HC Wainwright analysts commented, "Our current target is based on a 12-year DCF analysis primarily focused on VY-AADC in PD. Our DCF analysis is based on: beta of 1.62, terminal growth rate of 0.5%, risk premium of 4.93%, calculated WACC of 10.0%, and tax rate of 15% beginning in FY 2030." (8/12/2019)
Has Voyager Therapeutics been receiving favorable news coverage?
Media headlines about VYGR stock have trended extremely negative on Tuesday, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Voyager Therapeutics earned a news impact score of -4.3 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View News Stories for Voyager Therapeutics.
Are investors shorting Voyager Therapeutics?
Voyager Therapeutics saw a increase in short interest in September. As of September 30th, there was short interest totalling 3,220,000 shares, an increase of 17.5% from the August 30th total of 2,740,000 shares. Based on an average daily trading volume, of 411,400 shares, the short-interest ratio is presently 7.8 days. Currently, 13.7% of the shares of the stock are sold short. View Voyager Therapeutics' Current Options Chain.
Who are some of Voyager Therapeutics' key competitors?
Some companies that are related to Voyager Therapeutics include Acceleron Pharma (XLRN), Halozyme Therapeutics (HALO), Crispr Therapeutics (CRSP), Regenxbio (RGNX), Momenta Pharmaceuticals (MNTA), Denali Therapeutics (DNLI), Coherus Biosciences (CHRS), Audentes Therapeutics (BOLD), Orchard Therapeutics (ORTX), Editas Medicine (EDIT), Alector (ALEC), Sangamo Therapeutics (SGMO), Fate Therapeutics (FATE), Aerie Pharmaceuticals (AERI) and BAVARIAN NORDIC/S (BVNRY).
What other stocks do shareholders of Voyager Therapeutics own?
Who are Voyager Therapeutics' key executives?
Voyager Therapeutics' management team includes the folowing people:
- Mr. Matthew P. Ottmer, Chief Operating Officer (Age 48)
- Dr. Steven M. Paul, Exec. Science Advisor & Director (Age 68)
- Mr. G. Andre Turenne, CEO, Pres & Director
- Dr. Krystof Bankiewicz M.D., Ph.D., Founder
- Dr. Guangping Gao Ph.D., Founder
Who are Voyager Therapeutics' major shareholders?
Voyager Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Bailard Inc. (0.32%), Strs Ohio (0.10%) and Meeder Asset Management Inc. (0.02%). Company insiders that own Voyager Therapeutics stock include Bernard Ravina, Dinah PhD Sah, Glenn Pierce, James A Geraghty, Jane Henderson and Neurocrine Biosciences Inc. View Institutional Ownership Trends for Voyager Therapeutics.
Which major investors are selling Voyager Therapeutics stock?
Which major investors are buying Voyager Therapeutics stock?
VYGR stock was acquired by a variety of institutional investors in the last quarter, including Bailard Inc. and Strs Ohio. Company insiders that have bought Voyager Therapeutics stock in the last two years include Glenn Pierce, James A Geraghty and Neurocrine Biosciences Inc. View Insider Buying and Selling for Voyager Therapeutics.
How do I buy shares of Voyager Therapeutics?
Shares of VYGR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Voyager Therapeutics' stock price today?
One share of VYGR stock can currently be purchased for approximately $15.45.
How big of a company is Voyager Therapeutics?
Voyager Therapeutics has a market capitalization of $570.57 million and generates $7.62 million in revenue each year. The company earns $-88,290,000.00 in net income (profit) each year or ($2.75) on an earnings per share basis. Voyager Therapeutics employs 123 workers across the globe.View Additional Information About Voyager Therapeutics.
What is Voyager Therapeutics' official website?
How can I contact Voyager Therapeutics?
Voyager Therapeutics' mailing address is 75 SIDNEY STREET, CAMBRIDGE MA, 02139. The company can be reached via phone at 857-259-5340 or via email at [email protected]
MarketBeat Community Rating for Voyager Therapeutics (NASDAQ VYGR)
MarketBeat's community ratings are surveys of what our community members think about Voyager Therapeutics and other stocks. Vote "Outperform" if you believe VYGR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VYGR will underperform the S&P 500 over the long term. You may vote once every thirty days.
